|598.54||-5.74||-0.95%||Vol 850.10K||1Y Perf 97.56%|
|Jun 4th, 2020 16:00 DELAYED|
|-3.28 -0.54%||- -%|
|Target Price||558.11||Analyst Rating||Moderate Buy 1.95|
|Potential %||-6.75||Finscreener Ranking||★★★★ 55.60|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★ 58.90|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 75.74|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||65.85B||Earnings Rating||Sell|
|Price Range Ratio 52W %||94.19||Earnings Date||5th May 2020|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|10 Years||2 023.24%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||4.89|
|EPS Growth Next 5 Years %||19.70|
|Avg. Weekly Volume||2.40M|
|Avg. Monthly Volume||2.00M|
|Avg. Quarterly Volume||1.58M|
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock closed at 598.54 per share at the end of the most recent trading day (a -0.95% change compared to the prior day closing price) with a volume of 851.81K shares and market capitalization of 65.85B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 7400 people. Regeneron Pharmaceuticals Inc. CEO is Leonard S. Schleifer.
The one-year performance of Regeneron Pharmaceuticals Inc. stock is 97.56%, while year-to-date (YTD) performance is 59.41%. REGN stock has a five-year performance of 10.96%. Its 52-week range is between 271.37 and 618.71, which gives REGN stock a 52-week price range ratio of 94.19%
Regeneron Pharmaceuticals Inc. currently has a PE ratio of 30.80, a price-to-book (PB) ratio of 5.68, a price-to-sale (PS) ratio of 8.31, a price to cashflow ratio of 31.50, a PEG ratio of 2.32, a ROA of 15.93%, a ROC of 20.04% and a ROE of 21.13%. The company’s profit margin is 28.56%, its EBITDA margin is 33.60%, and its revenue ttm is $7.98 Billion , which makes it $72.10 revenue per share.
Of the last four earnings reports from Regeneron Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $4.89 for the next earnings report. Regeneron Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Regeneron Pharmaceuticals Inc. is Moderate Buy (1.95), with a target price of $558.11, which is -6.75% compared to the current price. The earnings rating for Regeneron Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Regeneron Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Regeneron Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 19.41, ATR14 : 24.56, CCI20 : 122.28, Chaikin Money Flow : 0.33, MACD : 17.16, Money Flow Index : 58.08, ROC : 7.34, RSI : 57.91, STOCH (14,3) : 79.14, STOCH RSI : 0.60, UO : 65.61, Williams %R : -20.86), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Regeneron Pharmaceuticals Inc. in the last 12-months were: Andrew J Murphy (Sold 8 000 shares of value $2 727 279 ), Arthur Frederick Ryan (Option Excercise at a value of $18 729 668), Arthur Frederick Ryan (Sold 50 471 shares of value $27 791 038 ), Christopher R. Fenimore (Option Excercise at a value of $225 616), Christopher R. Fenimore (Sold 2 882 shares of value $1 218 761 ), Daniel P. Van Plew (Option Excercise at a value of $5 455 348), Daniel P. Van Plew (Sold 55 225 shares of value $29 489 318 ), George D. Yancopoulos (Option Excercise at a value of $17 982 559), George D. Yancopoulos (Sold 235 938 shares of value $105 059 775 ), George L. Sing (Option Excercise at a value of $616 800), George L. Sing (Sold 25 250 shares of value $11 078 750 ), Huda Y. Zoghbi (Option Excercise at a value of $2 005 846), Huda Y. Zoghbi (Sold 5 118 shares of value $2 899 461 ), Joseph J. Larosa (Option Excercise at a value of $2 660 033), Joseph J. Larosa (Sold 24 813 shares of value $13 458 373 ), Joseph L. Goldstein (Option Excercise at a value of $167 100), Joseph L. Goldstein (Sold 9 500 shares of value $4 217 362 ), Leonard S. Schleifer (Option Excercise at a value of $16 210 375), Leonard S. Schleifer (Sold 150 922 shares of value $85 908 038 ), Marc Tessier-Lavigne (Option Excercise at a value of $3 425 244), Marc Tessier-Lavigne (Sold 29 279 shares of value $14 171 206 ), Michael S. Brown (Option Excercise at a value of $4 908 274), Michael S. Brown (Sold 12 309 shares of value $4 921 128 ), Neil Stahl (Option Excercise at a value of $4 452 675), Neil Stahl (Sold 41 599 shares of value $18 229 506 ), P. Roy Vagelos (Option Excercise at a value of $5 736 051), P. Roy Vagelos (Sold 223 585 shares of value $111 990 855 ), Robert E. Landry (Option Excercise at a value of $9 953 550), Robert E. Landry (Sold 9 006 shares of value $4 743 561 )
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.